
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences is poised for continued growth, especially with the anticipated market adoption of its Cologuard test, which is expected to increase from approximately 15% market share to over 40% in the long term. The company has revised its 2025 guidance upward beyond its recent third-quarter performance, driven by strong revenue growth, highlighted by a 22% year-over-year increase in its core screening business. Additionally, the successful launch of the Cancerguard blood test, along with positive Adjusted EBITDA generation, reinforces a promising financial outlook as Exact Sciences aims to triple the number of individuals screened by 2027.
Bears say
Exact Sciences faces several challenges that contribute to a negative outlook on its stock. The company's reliance on promotional marketing for Cologuard, along with a history of net losses, raises concerns about its ability to achieve and sustain GAAP profitability. Additionally, projected revenue estimates for 2027, although potentially conservative, indicate a shortfall from targets, reflecting uncertainty surrounding future sales performance amid anticipated acquisitions and market competition.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares